1.1 Research Scope

1.2 Research Methodology

1.2 Research Methodology (Continued)

1.3 Key Findings

2.1 Overview of Key Liquid Biopsy (LB) Markers

2.2 Key Liquid Biopsy Markers Comprise Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) and Extracellular Vesicles (EVs)

3.1 Next-Generation Sequencing Platforms Likely to Fuel ctDNA Analysis

3.2 Overview of PCR-Based Technologies for ctDNA Analysis

3.3 Next-Generation Sequencing Tools for ctDNA Assessment

3.4 Emerging ctDNA Technologies Likely to Enable Comprehensive genome Profiling

3.5 ctDNA Leads Profiling and Therapy Monitoring Applications in Clinical Trial Studies

3.6 China Leads the Global Patent Landscape for ctDNA-based Technologies

3.7 Research Funding in US for ctDNA-based Projects Exceed $50M in 2015-2016 Period

3.8 ctDNA Biomarkers Studies Likely to Accelerate Disease and Treatment Profiling Applications

3.9 Leveraging Epigenetic Tools across Cancer Diagnostics

3.10 Enabling Personalized Management of Cancer

4.1 Circulating Tumor Cells Enable Comprehensive Analysis of Cancer

4.2 Cellular Analytics for CTCs Enable Prognostic Insights for Cancer

4.3 Technologies Facilitating Molecular Analysis of CTCs Likely to Transform Cancer Management

4.4 Emerging Use of Microfluidic and Imaging Technologies Enhance CTC Analysis

4.5 China Leads the Global Patent Landscape for CTCs

4.6 NIH funding for CTC-based Projects Exceeded $150 million during 2015-2016

4.7 CTCs Likely to Lead Disease Profiling, Treatment Profiling and Prognostic Applications across Several Cancers

4.8 Combining ctDNA and CTC Analyses for Liquid Biopsy Assays

4.9 US FDA Approved CTC Assay

5.1 Exosomes Likely to Garner Growing Attention across Cancer Liquid Biopsy Applications

5.2 Affinity Capture and Microfluidics techniques Likely to Enhance Exosome Isolation and Detection in the Near Future

5.3 Advances across Proteomic and Nucleic Acid Assay Techniques Likely to Enhance Exosome Markers Detection

5.4 North America Leads the Global Patent Landscape for Extracellular Vesicle-based Technologies

5.5 US Research Funding for EV-based Technologies Exceeds $250 Million during 2015-2016

5.6 Exosomal Markers Likely to Lead Disease Profiling and Treatment Monitoring Applications

5.7 Exosome-based Liquid Biopsy Assays for Precision Oncology

5.8 Novel Platforms for Enhanced Isolation of EVs

6.1 Summary of Key Technology Drivers

6.2 Technology Advancements and Rising Preference for Minimally Invasive Methods Likely to Fuel Liquid Biopsy Platforms

6.3 Summary of Key Technology Challenges

6.4 Enhancing Assay Accuracy and Clinical Utility of Biomarkers Constitute Key Challenges across Liquid Biopsy Tests

6.5 Liquid Biopsy Platforms Likely to Transform Disease Profiling and Precision Medicine Applications

7.1 Growth Opportunity 1: ctDNA

7.2 Growth Opportunity 2: CTCs

7.3 Growth Opportunity 3: EVs

7.4 Strategic Imperatives for Success and Growth

8.1 Key Contacts

8.1 Key Contacts (continued)

Legal Disclaimer

9.1 The Frost & Sullivan Story

9.2 Value Proposition: Future of Your Company & Career

9.3 Global Perspective

9.4 Industry Convergence

9.5 360º Research Perspective

9.6 Implementation Excellence

9.7 Our Blue Ocean Strategy